🇺🇸 FDA
Patent

US 9226971

N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides

granted A61KA61K31/165A61K47/60

Quick answer

US patent 9226971 (N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides) held by Nektar Therapeutics expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/165, A61K47/60, A61P, A61P25/08